Dataset Information

Next Generation Sequencing Facilitates Quantitative Analysis of primary cultured astrocytes treated with SB431542, Ro5-3335 and HLM006474 inhibitors.

ABSTRACT: Purpose: The goals of this study are to investigate differential genes expression with RNA-seq in primary cultured astrocytes treated with the Tgf-beta1 receptor inhibitor SB431542, the Runx1 inhibitor Ro5-3335 and the E2f1 inhibitor HLM006474. Methods: Primary cultured astrocytes were isolated from either C57BL/6 wild-type neonatal mice. Total RNA was extracted from SB431542, Ro5-3335 and HLM006474-treated astrocytes with the RNeasy Plus Micro Kit (Qiagen; 74034). mRNA profiles were generated by deep sequencing using Illumina NovaSeq 6000. The sequence reads that passed quality filters were aligned to the mouse reference genome (GRCm38) using the STAR software package. Differential expression analysis were performed using the R package DESeq2. qPCR validation was performed using SYBR Green assays. Results: After quality control and data filtering, about 50 million raw reads per sample were obtained. We mapped sequence reads per sample to the mouse reference genome (GRCm38) and identified 35825 transcripts vehicle, SB431542, Ro5-3335 and HLM006474 group. Differentially expressed genes (DEGs) were analyzed with a fold change ≥1.5 and p value <0.05. A total of 748 DEGs were identified in SB431542 group with 347 upregulated genes and 401 downregulated genes. A total of 397 DEGs were identified in Ro5-3335 group with 82 upregulated genes and 315 downregulated genes. A total of 856 DEGs were identified in HLM006474 group with 216 upregulated genes and 640 downregulated genes. Hierarchical clustering heat map, pathway enrichment and analysis of DEGs were performed. Conclusions: Our RNA-seq dataset represents the differentially expressed genes in the C57BL/6 astrocytes treated with SB431542, Ro5-3335 and HLM006474-treated astrocytes.

ORGANISM(S): Mus musculus

PROVIDER: GSE174523 | GEO | 2022/11/23

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Purpose: We applied the next-generation sequencing to explore the differential gene expression in CAD cells differentiated with dexamethasone (Dex), compared to the undifferentiated cells using Illumna -based RNA-sequencing. Methods: Total RNAs were extracted from undifferentiated CAD cells and Dex-differentiated cells (5 days). Three independent samples were collected from both experimental groups. Samples then underwent to the sequencing step performed on NextSeq with a 75 base-pair end read length. Quality filtered reads were mapped to the mouse reference genome (GRCm38.p6). Feature Counts software was implemented to obtain raw counts for all mouse genes. The gene counts were used for differential expression analysis with the DESeq2 package to identify differentially expressed genes (DEGs) in the Dex-differentiated CAD cells, as compared to the undifferentiated CAD cells. Results: The sequence reads (expression level) per sample was obtained in a range of 9.8-11.2 million. The high quality of sequence reads was mapped to the mouse reference transcriptome (GRCm38.p6). The gene counts were used for differential expression analysis. The sample-to-sample distance demonstrated that the clustering of the undifferentiated groups was completely separated from the clustering of Dex-differentiated groups. A PCA plot showed that there was a huge variation (PC 1 =99%) between the Dex-differentiated group and the undifferentiated group but less variation was observed within the same group (PC2 = 0%). These statistic profiles indicate that the transcriptomic profile between Dex-differentiated CAD cells and undifferentiated CAD cells had the different pattern. A total of 1,183 differentially expressed genes (DEGs) were identified in the Dex-differentiated CAD cells compared to the undifferentiated CAD cells (false discovery rate < 0.01 and |log2 [fold change] | > 2). Of these, 803 and 380 genes were significantly upregulated and downregulated in the Dex-differentiated group, respectively. Conclusion: Dexamethasone causes extensive changes in gene expression of CAD cells.

Project description:Purpose: mRNA-sequencing has revolutionized systems-based analysis of cellular pathways. The goals of this study are to systemically research the biological functions of SOD1 in ROS signaling pathway using specific SOD1 inhibitor-LD100 and its validated siRNA. Methods: We reported the mRNA-sequencing data of HeLa cells (designated as C), LD100-treated HeLa cells (L), SOD1 knockdown HeLa cells (S), DU145 cells (DC), LD100-treated DU145 cells (DL), RWPE-1 cells (RC) and LD100-treated RWPE-1 cells (RL). All the samples were sequenced in triplicate, using Illumina HiSeq PE150. Remaining paired-end clean reads were aligned to the reference genome (GRCh38) using HISAT aligner. After calculating the reads numbers mapped to each gene by HTSeq, we estimated gene expression levels via FPKM. Differential expression analysis of two different groups was performed using the DESeq R package, which was based on a model of negative binomial distribution. Results: A total of 133,070,980 reads in the control group, 128,097,025 reads in the SOD1 knockdown group, and 129,315,055 in the LD100-treated group were mapped to the reference genome. The total of 4513 differentially expressed genes (DEGs) was identified in the knockdown group, and the total of 2650 DEGs was identified in the SOD1 inhibition group compared to the control group. A total of 170,657,327 and 175,502,302 reads in the control group of DU145 and RWPE-1, 181,591,462 and 179,503,168 reads in the LD100-treated group of DU145 and RWPE-1 were respectively mapped to the reference genome. Among them, 8806 DEGs were identified in the LD100-treated DU145 cells compared to the control, but only 1503 DEGs were identified in the LD100-treated RWPE-1 cells compared to the control. Conclusions: The global transcriptomic data on HeLa, DU145 and RWPE-1 after SOD1 inhibition using its specific inhibitor-LD100 indicated that the most changed expression upon this interruption of ROS homeostasis is the key genes in plenty of signaling pathways inside cancer cells, not inside normal cells, although mRNA levels of numerous genes are altered in three lines of cells. The modulation of gene expression leads to repression of multiple signaling pathways including ERK, PI3K and NF-KB and their crosstalk to promote cell growth and activation of the signaling pathways to cause both cell cycle arrest and apoptosis. These modulated signaling pathways constitute a ROS signaling network, and SOD1 is a master hub in modulation of the network to selectively kill cancer cells.

Project description:To examine the role of platelets in mouse monocyte function, we administered anti-GPIba antibody to deplete platelets or IgG as a control to 48 mice. After 12 hours, mice were either exposed to LPS or PBS (as a sham control) for 3 hours. Peripheral blood mononuclear cells (PBMCs) were collected, and monocytes were sorted into QIAzol lysis buffer. The experimental setup included 4 conditions, with each condition repeated 3 times. In each experiment, the blood from 4 mice was pooled to generate biological replicates of 12 mice, distributed into 4 groups: Sham mice (IgG) treated with PBS (n = 3) Sham mice (IgG) treated with LPS (n = 3) Platelet-depleted mice (anti-GPIba) treated with PBS (n = 3) Platelet-depleted mice (anti-GPIba) treated with LPS (n = 3) After these treatments, mouse Ly6G− IA/IE− CD45+ CD11b+ CD115+ monocytes were FACS-sorted directly into Quiazol for RNA extraction. The lysed samples were sent to GENEWIZ for RNA isolation and bulk RNA-seq analysis. RNA extraction and library preparation were conducted according to the GENEWIZ (Azenta Life Sciences) pipeline. Ultra-low input RNA-Seq was performed on Illumina HiSeq PE 2x150 bp with approximately 350M reads. Subsequently, reads were mapped to the Mus musculus GRCm38 reference genome (ENSEMBL) using the STAR aligner v.2.5.2b, and unique gene hit counts were generated with featureCounts from the Subread package v.1.5.2. Standard analysis was performed by GENEWIZ, including differential gene expression analysis using DESeq2. p-values and log2 fold changes were calculated using the Wald test, with genes meeting criteria of adjusted p-value < 0.05 and absolute fold change > 2 considered significantly differentially expressed genes (DEGs). Gene ontology (GO) analysis of significant DEGs was conducted by GENEWIZ (Azenta Life Sciences) using the Fisher exact test.\\" *Our goal is to assess the alternations on transcription levels (mRNA-Seq) between the different groups. Twelve samples contain 500 - 10000 mouse monocytes that were directly sorted into 1 ml QIAzol. **Experimental setting: samples were generated from three independent experiments (biological replicates N1, N2 and N3), each on a different day. Each experiment consisted of 4 different groups: Group 1: treated with IgG + PBS Group 2: treated with IgG + LPS challenge Group 3: treated with AntiGPIb + PBS Group 4: treated with AntiGPIb + LPS challenge First run with biological replicates Nr. 1 (indicated as \\"N1\\") contained samples 1 - 4. Second run with biological replicates Nr. 2 (indicated as \\"N2\\") contained samples 5 - 8. Third run with biological replicates Nr. 3 (indicated as \\"N3\\") contained samples 9 - 12. Experimental questions/analysis: 1) what is the effect of AntiGPIb treatment w.o LPS challenge? i.e. \\"Group 3 (Treatment) vs. Group 1(Ctrl)\\" 2) what is the effect of LPS in \\"Group 2 (Treatment) vs. Group 1 (Ctrl)\\" as well as \\"Group 4 (Treatment) vs. Group 3 (Ctrl)\".

Dataset Information

Next Generation Sequencing Facilitates Quantitative Analysis of primary cultured astrocytes treated with SB431542, Ro5-3335 and HLM006474 inhibitors.

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets